$GOCO
GoHealth, Inc. Stock $goco

$goco Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000180822024000017 Filed on March 14, 2024

Income Statement

Concept	2023 Q4	2023
Revenue	$276.7M	$734.7M
YoY Change	298.84%	16.31%
Cost Of Revenue	$41.09M	$159.0M
YoY Change	99.16%	-15.3%
Gross Profit	$235.6M	$575.7M
YoY Change	383.34%	29.66%
Gross Profit Margin	85.15%	78.36%
Selling, General & Admin	$101.3M	$303.4M
YoY Change	22.42%	-7.84%
% of Gross Profit	43.01%	52.7%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$26.85M	$11.69M
YoY Change	1.02%	-89.07%
% of Gross Profit	11.4%	2.03%
Operating Expenses	$210.6M	$644.7M
YoY Change	15.93%	-11.09%
Operating Profit	$25.06M	-$81.68M
YoY Change	-118.86%	-70.95%
Interest Expense	-$17.75M	$69.47M
YoY Change	2.51%	-221.73%
% of Operating Profit	-70.83%
Other Income/Expense, Net	$776.0K	$37.00K
YoY Change	1452.0%	-100.15%
Pretax Income	-$1.915M	-$151.1M
YoY Change	-98.73%	-59.77%
Income Tax	$379.0K	$154.0K
% Of Pretax Income
Net Earnings	-$1.226M	-$63.26M
YoY Change	-98.0%	-57.46%
Net Earnings / Revenue	-0.44%	-8.61%
Basic Earnings Per Share		-$7.19
Diluted Earnings Per Share	-$0.13	-$7.19
COMMON SHARES
Basic Shares Outstanding		9.292M shares
Diluted Shares Outstanding		9.292M shares

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.81M	$90.81M
YoY Change	451.56%	451.56%
Cash & Equivalents	$90.81M	$90.81M
Short-Term Investments
Other Short-Term Assets	$49.17M	$49.17M
YoY Change	-14.63%	-14.63%
Inventory
Prepaid Expenses
Receivables	$250.0K	$250.0K
Other Receivables	$336.2M	$336.2M
Total Short-Term Assets	$476.4M	$476.4M
YoY Change	14.93%	14.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$48.84M	$48.84M
YoY Change	4.43%	4.43%
Goodwill
YoY Change
Intangibles	$396.6M
YoY Change	-20.79%
Long-Term Investments
YoY Change
Other Assets	$2.256M	$2.256M
YoY Change	31.09%	31.09%
Total Long-Term Assets	$1.023B	$1.023B
YoY Change	-17.8%	-17.8%
TOTAL ASSETS
Total Short-Term Assets	$476.4M	$476.4M
Total Long-Term Assets	$1.023B	$1.023B
Total Assets	$1.500B	$1.500B
YoY Change	-9.63%	-9.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.71M	$17.71M
YoY Change	16.88%	16.88%
Accrued Expenses	$86.25M	$92.05M
YoY Change	38.43%	47.74%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$75.00M	$75.00M
YoY Change	1323.15%	1323.15%
Total Short-Term Liabilities	$370.0M	$370.0M
YoY Change	39.39%	39.39%
LONG-TERM LIABILITIES
Long-Term Debt	$422.7M	$422.7M
YoY Change	-16.26%	-16.26%
Other Long-Term Liabilities	$9.095M	$251.9M
YoY Change	-96.94%	-15.28%
Total Long-Term Liabilities	$674.6M	$674.6M
YoY Change	-15.9%	-15.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$370.0M	$370.0M
Total Long-Term Liabilities	$674.6M	$674.6M
Total Liabilities	$1.045B	$1.219B
YoY Change	-22.12%	-9.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$420.3M
YoY Change	17.72%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$231.0M	$280.3M
YoY Change
Total Liabilities & Shareholders Equity	$1.500B	$1.500B
YoY Change	-9.63%	-9.63%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.226M	-$63.26M
YoY Change	-98.0%	-57.46%
Depreciation, Depletion And Amortization	$26.85M	$11.69M
YoY Change	1.02%	-89.07%
Cash From Operating Activities	$71.30M	$109.1M
YoY Change	-273.91%	79.2%
INVESTING ACTIVITIES
Capital Expenditures	$5.645M	$13.73M
YoY Change	298.66%	1.63%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$5.645M	-$13.73M
YoY Change	298.66%	1.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.087M	-$21.11M
YoY Change	-99.31%	-81.66%
NET CHANGE
Cash From Operating Activities	71.30M	$109.1M
Cash From Investing Activities	-5.645M	-$13.73M
Cash From Financing Activities	-1.087M	-$21.11M
Net Change In Cash	64.57M	$74.35M
YoY Change	-132.45%	-209.88%
FREE CASH FLOW
Cash From Operating Activities	$71.30M	$109.1M
Capital Expenditures	$5.645M	$13.73M
Free Cash Flow	$65.66M	$95.41M
YoY Change	-254.79%	101.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39390
CY2023	dei	Entity Registrant Name EntityRegistrantName	GoHealth, Inc.
CY2023	dei	Local Phone Number LocalPhoneNumber	386-8200
CY2023	dei	Security12b Title Security12bTitle	Class A Common Stock,$0.0001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	GOCO
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	542399000	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1062000	usd
CY2023	us-gaap	Interest Expense InterestExpense	69472000	usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-26.80
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	94057000	usd
CY2023	goco	Restructuring Charges Excluding Executive Related Severance Expenses RestructuringChargesExcludingExecutiveRelatedSeveranceExpenses	0	usd
CY2022	goco	Restructuring Charges Excluding Executive Related Severance Expenses RestructuringChargesExcludingExecutiveRelatedSeveranceExpenses	12184000	usd
CY2021	goco	Restructuring Charges Excluding Executive Related Severance Expenses RestructuringChargesExcludingExecutiveRelatedSeveranceExpenses	0	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	816352000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	950341000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-81681000	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001808220
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-0563805
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	222 W Merchandise Mart Plaza, Suite 1750
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60654
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Chicago,
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
CY2023	dei	City Area Code CityAreaCode	312
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	88000000	usd
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Chicago, Illinois
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	734671000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	631675000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1062415000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	158961000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	187670000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	239335000	usd
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	205042000	usd
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	207559000	usd
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	365141000	usd
CY2023	us-gaap	Business Development BusinessDevelopment	209234000	usd
CY2022	us-gaap	Business Development BusinessDevelopment	260902000	usd
CY2021	us-gaap	Business Development BusinessDevelopment	319103000	usd
CY2023	us-gaap	Information Technology And Data Processing InformationTechnologyAndDataProcessing	43302000	usd
CY2022	us-gaap	Information Technology And Data Processing InformationTechnologyAndDataProcessing	46094000	usd
CY2021	us-gaap	Information Technology And Data Processing InformationTechnologyAndDataProcessing	48429000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	93069000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	116530000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	98183000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	94056000	usd
CY2023	goco	Impairment Loss Goodwill And Indefinite Lived Intangible Assets ImpairmentLossGoodwillAndIndefiniteLivedIntangibleAssets	10000000	usd
CY2022	goco	Impairment Loss Goodwill And Indefinite Lived Intangible Assets ImpairmentLossGoodwillAndIndefiniteLivedIntangibleAssets	0	usd
CY2021Q4	goco	Impairment Loss Goodwill And Indefinite Lived Intangible Assets ImpairmentLossGoodwillAndIndefiniteLivedIntangibleAssets	386553000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	1551862000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-318666000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-489447000	usd
CY2022	us-gaap	Interest Expense InterestExpense	57069000	usd
CY2021	us-gaap	Interest Expense InterestExpense	33505000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-11935000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	115000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	669000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-534218000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.19
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9292000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9292000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8445000	shares
CY2023	us-gaap	Profit Loss ProfitLoss	-151270000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-376384000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-534194000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	42000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-238000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-155000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-151228000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-376622000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-534349000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-87988000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-227831000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-344916000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-63240000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-148791000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-189433000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90809000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16464000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	27000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	89000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	250000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4703000	usd
CY2023Q4	goco	Contract With Customer Asset After Allowance For Credit Loss Commissions Receivable Current ContractWithCustomerAssetAfterAllowanceForCreditLossCommissionsReceivableCurrent	336215000	usd
CY2022Q4	goco	Contract With Customer Asset After Allowance For Credit Loss Commissions Receivable Current ContractWithCustomerAssetAfterAllowanceForCreditLossCommissionsReceivableCurrent	335796000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	49166000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	57593000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	476440000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	414556000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	575482000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	695637000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21995000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21483000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2256000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1721000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	26843000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	25282000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	396554000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	500611000	usd
CY2023Q4	us-gaap	Assets Assets	1499570000	usd
CY2022Q4	us-gaap	Assets Assets	1659290000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17705000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15148000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	86254000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53334000	usd
CY2023Q4	goco	Contract With Customer Liability Current Commissions Payable ContractWithCustomerLiabilityCurrentCommissionsPayable	118732000	usd
CY2022Q4	goco	Contract With Customer Liability Current Commissions Payable ContractWithCustomerLiabilityCurrentCommissionsPayable	122023000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5797000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8974000	usd
CY2023Q4	goco	Contract With Customer Liability Current Deferred Revenue ContractWithCustomerLiabilityCurrentDeferredRevenue	52403000	usd
CY2022Q4	goco	Contract With Customer Liability Current Deferred Revenue ContractWithCustomerLiabilityCurrentDeferredRevenue	50594000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	75000000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5270000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	14122000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10112000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	370013000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	265455000	usd
CY2023Q4	goco	Contract With Customer Liability Noncurrent Commissions Payable ContractWithCustomerLiabilityNoncurrentCommissionsPayable	203255000	usd
CY2022Q4	goco	Contract With Customer Liability Noncurrent Commissions Payable ContractWithCustomerLiabilityNoncurrentCommissionsPayable	253118000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39547000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	38367000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	422705000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	504810000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9095000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5839000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	674602000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	802134000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	654059000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	626269000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-127000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-144000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-420280000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-357023000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	231014000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	268759000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	174639000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	273640000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	405653000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1499570000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1659290000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-151270000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	939000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19549000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	42000	usd
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2295000	usd
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	3566000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	0	usd
CY2023	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	145000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	405653000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-376384000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	677000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27142000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-238000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	345000	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	943000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	0	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-534194000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	989000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27297000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-155000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	0	usd
CY2021	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	0	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	892490000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-151270000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-376384000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-534194000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	19549000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	27142000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	27297000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11691000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12945000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13451000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	94057000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	94057000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	94056000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3196000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2896000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2222000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-11935000	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	2687000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	25345000	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1062000	usd
CY2023	goco	Impairment Loss Goodwill And Indefinite Lived Intangible Assets ImpairmentLossGoodwillAndIndefiniteLivedIntangibleAssets	10000000	usd
CY2022	goco	Impairment Loss Goodwill And Indefinite Lived Intangible Assets ImpairmentLossGoodwillAndIndefiniteLivedIntangibleAssets	0	usd
CY2021	goco	Impairment Loss Goodwill And Indefinite Lived Intangible Assets ImpairmentLossGoodwillAndIndefiniteLivedIntangibleAssets	386553000	usd
CY2023	goco	Noncash Restructuring Charges NoncashRestructuringCharges	0	usd
CY2022	goco	Noncash Restructuring Charges NoncashRestructuringCharges	976000	usd
CY2021	goco	Noncash Restructuring Charges NoncashRestructuringCharges	0	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4016000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4017000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	5033000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	902000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	250000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5386000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12574000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2758000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-119706000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-231274000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	452950000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7512000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2140000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	18613000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2556000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-24795000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	30477000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	32920000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	546000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	25745000	usd
CY2023	goco	Increase Decrease In Contract With Customer Liability Deferred Revenue IncreaseDecreaseInContractWithCustomerLiabilityDeferredRevenue	1809000	usd
CY2022	goco	Increase Decrease In Contract With Customer Liability Deferred Revenue IncreaseDecreaseInContractWithCustomerLiabilityDeferredRevenue	50058000	usd
CY2021	goco	Increase Decrease In Contract With Customer Liability Deferred Revenue IncreaseDecreaseInContractWithCustomerLiabilityDeferredRevenue	-200000	usd
CY2023	goco	Increase Decrease In Contract With Customer Liability Commissions Payable IncreaseDecreaseInContractWithCustomerLiabilityCommissionsPayable	-53154000	usd
CY2022	goco	Increase Decrease In Contract With Customer Liability Commissions Payable IncreaseDecreaseInContractWithCustomerLiabilityCommissionsPayable	-3423000	usd
CY2021	goco	Increase Decrease In Contract With Customer Liability Commissions Payable IncreaseDecreaseInContractWithCustomerLiabilityCommissionsPayable	117489000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-8731000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6597000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4885000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	8113000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	8383000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-721000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	109141000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	60904000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-299006000	usd
CY2023	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	13732000	usd
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	13512000	usd
CY2021	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	19801000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13732000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13512000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19801000	usd
CY2023	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	15336000	usd
CY2022	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	160270000	usd
CY2021	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	298970000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	91000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023	goco	Proceeds From Issuance Of Temporary Equity ProceedsFromIssuanceOfTemporaryEquity	0	usd
CY2022	goco	Proceeds From Issuance Of Temporary Equity ProceedsFromIssuanceOfTemporaryEquity	50000000	usd
CY2021	goco	Proceeds From Issuance Of Temporary Equity ProceedsFromIssuanceOfTemporaryEquity	0	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1641000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2023	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	3566000	usd
CY2022	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	usd
CY2021	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2697000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4108000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2295000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	345000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	103000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	318000	usd
CY2023	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2022	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	565000000	usd
CY2023	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
CY2022	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
CY2021	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	5910000	usd
CY2023	goco	Proceeds From Payments For Advance To Affiliate Financing Activities ProceedsFromPaymentsForAdvanceToAffiliateFinancingActivities	0	usd
CY2022	goco	Proceeds From Payments For Advance To Affiliate Financing Activities ProceedsFromPaymentsForAdvanceToAffiliateFinancingActivities	0	usd
CY2021	goco	Proceeds From Payments For Advance To Affiliate Financing Activities ProceedsFromPaymentsForAdvanceToAffiliateFinancingActivities	3395000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-21106000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-115051000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	259089000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-238000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-155000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	74345000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-67897000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-59873000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16464000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84361000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	144234000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90809000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16464000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84361000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	55345000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	56920000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	28244000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	548000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	486000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	879000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	123000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	633000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts receivable, unbilled receivables and commissions receivable. The maximum exposure risk of these accounts is equal to the amounts stated on the Company’s Consolidated Balance Sheets. The Company places its cash with high-credit-quality financial institutions and, at times, such deposits may be in excess of federally insured limits. To date, the Company has not experienced any losses on its cash balances and periodic evaluations of the relative credit standing of the financial institutions are performed.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Accounts receivable, unbilled receivables and commissions receivable are primarily derived from customers located in North America. The Company performs ongoing credit evaluations of customers’ financial condition and requires no collateral from customers. The Company maintains an allowance for doubtful accounts and credit losses based upon the expected collectability of accounts receivable, unbilled receivables and commissions receivable.</span></div>
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	386600000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	10000000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	2700000	usd
CY2022Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	25300000	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1100000	usd
CY2023Q4	goco	Revenue From Contract With Customer Variable Consideration Disenrollment Period Threshold RevenueFromContractWithCustomerVariableConsiderationDisenrollmentPeriodThreshold	P90D
CY2023	us-gaap	Advertising Expense AdvertisingExpense	188300000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	178700000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	323300000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	11305000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10865000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	18404000	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	6949000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	11109000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	179000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	33642000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11589000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	86254000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	53334000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	2700000	usd
CY2022Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	25300000	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1100000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	10000000	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	386600000	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	4	segment
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	29113000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	18261000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	26843000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	25282000	usd
CY2023	us-gaap	Depreciation Depreciation	3900000	usd
CY2022	us-gaap	Depreciation Depreciation	6400000	usd
CY2021	us-gaap	Depreciation Depreciation	9300000	usd
CY2023	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	7800000	usd
CY2022	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	6500000	usd
CY2021	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	4200000	usd
CY2023Q4	goco	Accrued Bonuses And Commissions Current AccruedBonusesAndCommissionsCurrent	11794000	usd
CY2022Q4	goco	Accrued Bonuses And Commissions Current AccruedBonusesAndCommissionsCurrent	23752000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	10000000	usd
CY2022	goco	Impairment Loss Goodwill And Indefinite Lived Intangible Assets ImpairmentLossGoodwillAndIndefiniteLivedIntangibleAssets	0	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	728000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	404446000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	323554000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	396554000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	728000000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	310389000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	417611000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	500611000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	94057000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	94057000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	72800000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	23200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	23200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	16240000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	323554000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	5091000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	8053000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	497705000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	510080000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	75000000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5270000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	422705000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	504810000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	75000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	427796000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	502796000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-11900000	usd
CY2023	goco	Mandatory Prepayment Of Debt In Next12 Months MandatoryPrepaymentOfDebtInNext12Months	75000000	usd
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q3	goco	Stockholders Equity Note Number Of Shares Of Class A Common Stock Issued To Number Of Llc Interests Owned Required Ratio StockholdersEquityNoteNumberOfSharesOfClassACommonStockIssuedToNumberOfLLCInterestsOwnedRequiredRatio	1
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Debt Instrument Convertible Threshold Trading Days DebtInstrumentConvertibleThresholdTradingDays	20	day
CY2022Q3	us-gaap	Debt Instrument Convertible Threshold Consecutive Trading Days1 DebtInstrumentConvertibleThresholdConsecutiveTradingDays1	30	day
CY2022Q3	goco	Preferred Stock Convertible But Not Converted Calculation Of Purchase Price Percent Of Purchasers Original Investment Amount PreferredStockConvertibleButNotConvertedCalculationOfPurchasePricePercentOfPurchasersOriginalInvestmentAmount	1.60
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19564000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32124000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27297000	usd
CY2020Q3	goco	Number Of Shares Of Llc Interests To Class B Common Stock Ratio NumberOfSharesOfLLCInterestsToClassBCommonStockRatio	1
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	436000	shares
CY2022Q4	goco	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	62.63
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	100000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.30
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5000	shares
CY2023	goco	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	145.79
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	21000	shares
CY2023	goco	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue	131.05
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	41000	shares
CY2023	goco	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue	149.04
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	469000	shares
CY2023Q4	goco	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	39.54
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	383000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	153000	shares
CY2023Q4	goco	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	88.81
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	96000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2400000	usd
CY2022Q2	goco	Share Based Compensation Arrangement By Share Based Payment Award Options Repricing Trailing Trading Days For Stock Closing Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingTrailingTradingDaysForStockClosingPrice	20	day
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	800000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-151270000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-376384000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-534194000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-88013000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-227678000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-344837000	usd
CY2023	goco	Net Income Loss Attributable To Parent Subsequent To Reorganization Transactions NetIncomeLossAttributableToParentSubsequentToReorganizationTransactions	-63257000	usd
CY2022	goco	Net Income Loss Attributable To Parent Subsequent To Reorganization Transactions NetIncomeLossAttributableToParentSubsequentToReorganizationTransactions	-148706000	usd
CY2021	goco	Net Income Loss Attributable To Parent Subsequent To Reorganization Transactions NetIncomeLossAttributableToParentSubsequentToReorganizationTransactions	-189357000	usd
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	3566000	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	943000	usd
CY2021	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-66823000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-66823000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-149649000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-149649000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-189357000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-189357000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9292000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9292000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8445000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8445000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7066000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7066000	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.19
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.19
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-17.72
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-17.72
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-26.80
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-26.80
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-151321000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-376121000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-534929000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	205000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	501000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	711000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-151116000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-375620000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-534218000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	7000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-87000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	100000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	65000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	140000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	183000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	256000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	151000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	289000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	234000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	348000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-190000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	124000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-68000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	3000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	3000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	475000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-258000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	154000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	764000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-24000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.012
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.018
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.016
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.122
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.127
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.135
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.102
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.106
CY2023	goco	Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRatePercent	-0.095
CY2022	goco	Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRatePercent	0.000
CY2021	goco	Effective Income Tax Rate Reconciliation Change In Deferred Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxRatePercent	0.014
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.014
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000
CY2023Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	149237000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	201585000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	91607000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	77148000	usd
CY2023Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	9975000	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	7887000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	548000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	997000	usd
CY2023Q4	goco	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	241000	usd
CY2022Q4	goco	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	251000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	681000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	648000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	251741000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	289064000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	251500000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	288813000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	241000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	251000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	241000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	248000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	241000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	248000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	3000	usd
CY2023	goco	Deferred Tax Asset Basis Difference In Investment Increase Decrease Amount DeferredTaxAssetBasisDifferenceInInvestmentIncreaseDecreaseAmount	-36100000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	149200000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2020Q3	goco	Tax Receivable Agreement Payment Amount Percent Of Realized Or Realizable Income Tax Benefits TaxReceivableAgreementPaymentAmountPercentOfRealizedOrRealizableIncomeTaxBenefits	0.85
CY2020Q3	goco	Tax Receivable Agreement Remaining Percent Of Tax Benefits That May Be Realized TaxReceivableAgreementRemainingPercentOfTaxBenefitsThatMayBeRealized	0.15
CY2023Q4	goco	Tax Receivable Agreement Liability TaxReceivableAgreementLiability	800000	usd
CY2022Q4	goco	Tax Receivable Agreement Liability TaxReceivableAgreementLiability	600000	usd
CY2023	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	0	usd
CY2022	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	-275700000	usd
CY2021	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	-165300000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	734671000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	631675000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1062415000	usd
CY2023Q4	goco	Contract With Customer Liability Revenue Share ContractWithCustomerLiabilityRevenueShare	14800000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	45300000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	100000	usd
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	200000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	102000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	340000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	7952000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8286000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	7815000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	57000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	420000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	474000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	852000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	689000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	134000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	1577000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	1243000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	366000	usd
CY2023	us-gaap	Lease Cost LeaseCost	7284000	usd
CY2022	us-gaap	Lease Cost LeaseCost	8254000	usd
CY2021	us-gaap	Lease Cost LeaseCost	8397000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	2700000	usd
CY2022Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	25300000	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1100000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9727000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8845000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7761000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8007000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	7033000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	20443000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	61816000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	16472000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	45344000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	12383000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	10380000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	6652000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6735000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	26405000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1831000	usd
CY2023	goco	Reduction In Operating Lease Right Of Use Asset Due To Reassessment Of Lease Terms ReductionInOperatingLeaseRightOfUseAssetDueToReassessmentOfLeaseTerms	0	usd
CY2023	goco	Reduction In Operating Lease Liability Due To Reassessment Of Lease Terms ReductionInOperatingLeaseLiabilityDueToReassessmentOfLeaseTerms	0	usd
CY2022	goco	Reduction In Operating Lease Liability Due To Reassessment Of Lease Terms ReductionInOperatingLeaseLiabilityDueToReassessmentOfLeaseTerms	4155000	usd
CY2022	goco	Reduction In Operating Lease Right Of Use Asset Due To Reassessment Of Lease Terms ReductionInOperatingLeaseRightOfUseAssetDueToReassessmentOfLeaseTerms	4155000	usd
CY2021	goco	Reduction In Operating Lease Right Of Use Asset Due To Reassessment Of Lease Terms ReductionInOperatingLeaseRightOfUseAssetDueToReassessmentOfLeaseTerms	0	usd
CY2021	goco	Reduction In Operating Lease Liability Due To Reassessment Of Lease Terms ReductionInOperatingLeaseLiabilityDueToReassessmentOfLeaseTerms	0	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.081
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.062
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	12000000	usd
CY2023	goco	Related Party Transaction Lease Payments RelatedPartyTransactionLeasePayments	6000000	usd
CY2022	goco	Related Party Transaction Lease Payments RelatedPartyTransactionLeasePayments	3900000	usd
CY2021	goco	Related Party Transaction Lease Payments RelatedPartyTransactionLeasePayments	1300000	usd
CY2022Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	828	position
CY2022Q3	goco	Restructuring And Related Cost Number Of Positions Eliminated Percent Of Workforce RestructuringAndRelatedCostNumberOfPositionsEliminatedPercentOfWorkforce	0.237
CY2023	goco	Restructuring Charges Excluding Executive Related Severance Expenses RestructuringChargesExcludingExecutiveRelatedSeveranceExpenses	0	usd
CY2022	goco	Employee Related Benefits Restructuring Charges EmployeeRelatedBenefitsRestructuringCharges	11076000	usd
CY2022	us-gaap	Other Restructuring Costs OtherRestructuringCosts	1108000	usd
CY2022	goco	Restructuring Charges Excluding Executive Related Severance Expenses RestructuringChargesExcludingExecutiveRelatedSeveranceExpenses	12184000	usd
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	2083000	usd
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	usd
CY2023	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2022	us-gaap	Restructuring Charges RestructuringCharges	11208000	usd
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	1438000	usd
CY2022	us-gaap	Payments For Restructuring PaymentsForRestructuring	9125000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	645000	usd
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	2083000	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001808220-24-000017-index-headers.html	Edgar Link	pending
0001808220-24-000017-index.html	Edgar Link	pending
0001808220-24-000017.txt	Edgar Link	pending
0001808220-24-000017-xbrl.zip	Edgar Link	pending
compensationclawbackpoli.htm	Edgar Link	pending
compensationclawbackpoli001.jpg	Edgar Link	pending
compensationclawbackpoli002.jpg	Edgar Link	pending
compensationclawbackpoli003.jpg	Edgar Link	pending
compensationclawbackpoli004.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
goco-20231231.htm	Edgar Link	pending
goco-20231231.xsd	Edgar Link	pending
goco-20231231xex211xform10.htm	Edgar Link	pending
goco-20231231xex231xform10.htm	Edgar Link	pending
goco-20231231xex311xform10.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
goco-20231231xex312xform10.htm	Edgar Link	pending
goco-20231231xex321xform10.htm	Edgar Link	pending
goco-20231231xex322xform10.htm	Edgar Link	pending
goco-20231231_g1.jpg	Edgar Link	pending
goco-20231231_g2.jpg	Edgar Link	pending
gohealth-amendmentno11a0.htm	Edgar Link	pending
gohealth-amendmentno11a0001.jpg	Edgar Link	pending
gohealth-amendmentno11a0002.jpg	Edgar Link	pending
gohealth-amendmentno11a0003.jpg	Edgar Link	pending
gohealth-amendmentno11a0004.jpg	Edgar Link	pending
gohealth-amendmentno11a0005.jpg	Edgar Link	pending
gohealth-amendmentno11a0006.jpg	Edgar Link	pending
gohealth-amendmentno11a0007.jpg	Edgar Link	pending
gohealth-amendmentno11a0008.jpg	Edgar Link	pending
gohealth-amendmentno11a0009.jpg	Edgar Link	pending
gohealth-amendmentno11a0010.jpg	Edgar Link	pending
gohealth-amendmentno11a0011.jpg	Edgar Link	pending
gohealth-amendmentno11a0012.jpg	Edgar Link	pending
gohealth-amendmentno11a0013.jpg	Edgar Link	pending
gohealth-amendmentno11a0014.jpg	Edgar Link	pending
gohealth-amendmentno11a0015.jpg	Edgar Link	pending
gohealth-amendmentno11a0016.jpg	Edgar Link	pending
gohealth-amendmentno11a0017.jpg	Edgar Link	pending
gohealth-amendmentno11a0018.jpg	Edgar Link	pending
gohealth-amendmentno11a0019.jpg	Edgar Link	pending
gohealth-amendmentno11a0020.jpg	Edgar Link	pending
gohealth-amendmentno11a0021.jpg	Edgar Link	pending
gohealth-amendmentno11a0022.jpg	Edgar Link	pending
gohealth-amendmentno11a0023.jpg	Edgar Link	pending
gohealth-amendmentno11a0024.jpg	Edgar Link	pending
gohealth-amendmentno11a0025.jpg	Edgar Link	pending
gohealth-amendmentno11a0026.jpg	Edgar Link	pending
gohealth-amendmentno11a0027.jpg	Edgar Link	pending
gohealth-amendmentno11a0028.jpg	Edgar Link	pending
gohealth-amendmentno11a0029.jpg	Edgar Link	pending
gohealth-amendmentno11a0030.jpg	Edgar Link	pending
gohealth-amendmentno11a0031.jpg	Edgar Link	pending
gohealth-amendmentno11a0032.jpg	Edgar Link	pending
gohealth-amendmentno11a0033.jpg	Edgar Link	pending
gohealth-amendmentno11a0034.jpg	Edgar Link	pending
gohealth-amendmentno11a0035.jpg	Edgar Link	pending
gohealth-amendmentno11a0036.jpg	Edgar Link	pending
goco-20231231_def.xml	Edgar Link	unprocessable
goco-20231231_lab.xml	Edgar Link	unprocessable
goco-20231231_pre.xml	Edgar Link	unprocessable
goco-20231231_htm.xml	Edgar Link	completed
gohealth-amendmentno11a0037.jpg	Edgar Link	pending
gohealth-amendmentno11a0038.jpg	Edgar Link	pending
gohealth-amendmentno11a0039.jpg	Edgar Link	pending
gohealth-amendmentno11a0040.jpg	Edgar Link	pending
gohealth-amendmentno11a0041.jpg	Edgar Link	pending
gohealth-amendmentno11a0042.jpg	Edgar Link	pending
gohealth-amendmentno11a0043.jpg	Edgar Link	pending
gohealth-amendmentno11a0044.jpg	Edgar Link	pending
gohealth-amendmentno11a0045.jpg	Edgar Link	pending
gohealth-amendmentno11a0046.jpg	Edgar Link	pending
gohealth-amendmentno11a0047.jpg	Edgar Link	pending
gohealth-amendmentno11a0048.jpg	Edgar Link	pending
gohealth-amendmentno11a0049.jpg	Edgar Link	pending
gohealth-amendmentno11a0050.jpg	Edgar Link	pending
gohealth-amendmentno11a0051.jpg	Edgar Link	pending
gohealth-amendmentno11a0052.jpg	Edgar Link	pending
gohealth-amendmentno11a0053.jpg	Edgar Link	pending
gohealth-amendmentno11a0054.jpg	Edgar Link	pending
gohealth-amendmentno11a0055.jpg	Edgar Link	pending
gohealth-amendmentno11a0056.jpg	Edgar Link	pending
gohealth-amendmentno11a0057.jpg	Edgar Link	pending
gohealth-amendmentno11a0058.jpg	Edgar Link	pending
gohealth-amendmentno11a0059.jpg	Edgar Link	pending
gohealth-amendmentno11a0060.jpg	Edgar Link	pending
gohealth-amendmentno11a0061.jpg	Edgar Link	pending
gohealth-amendmentno11a0062.jpg	Edgar Link	pending
gohealth-amendmentno11a0063.jpg	Edgar Link	pending
gohealth-amendmentno11a0064.jpg	Edgar Link	pending
gohealth-amendmentno11a0065.jpg	Edgar Link	pending
gohealth-amendmentno11a0066.jpg	Edgar Link	pending
gohealth-amendmentno11a0067.jpg	Edgar Link	pending
gohealth-amendmentno11a0068.jpg	Edgar Link	pending
gohealth-amendmentno11a0069.jpg	Edgar Link	pending
gohealth-amendmentno11a0070.jpg	Edgar Link	pending
gohealth-amendmentno11a0071.jpg	Edgar Link	pending
gohealth-amendmentno11a0072.jpg	Edgar Link	pending
gohealth-amendmentno11a0073.jpg	Edgar Link	pending
gohealth-amendmentno11a0074.jpg	Edgar Link	pending
gohealth-amendmentno11a0075.jpg	Edgar Link	pending
gohealth-amendmentno11a0076.jpg	Edgar Link	pending
gohealth-amendmentno11a0077.jpg	Edgar Link	pending
gohealth-amendmentno11a0078.jpg	Edgar Link	pending
gohealth-amendmentno11a0079.jpg	Edgar Link	pending
gohealth-amendmentno11a0080.jpg	Edgar Link	pending
gohealth-amendmentno11a0081.jpg	Edgar Link	pending
gohealth-amendmentno11a0082.jpg	Edgar Link	pending
gohealth-amendmentno11a0083.jpg	Edgar Link	pending
gohealth-amendmentno11a0084.jpg	Edgar Link	pending
gohealth-amendmentno11a0085.jpg	Edgar Link	pending
gohealth-amendmentno11a0086.jpg	Edgar Link	pending
gohealth-amendmentno11a0087.jpg	Edgar Link	pending
gohealth-amendmentno11a0088.jpg	Edgar Link	pending
gohealth-amendmentno11a0089.jpg	Edgar Link	pending
gohealth-amendmentno11a0090.jpg	Edgar Link	pending
gohealth-amendmentno11a0091.jpg	Edgar Link	pending
gohealth-amendmentno11a0092.jpg	Edgar Link	pending
gohealth-amendmentno11a0093.jpg	Edgar Link	pending
gohealth-amendmentno11a0094.jpg	Edgar Link	pending
gohealth-amendmentno11a0095.jpg	Edgar Link	pending
gohealth-amendmentno11a0096.jpg	Edgar Link	pending
gohealth-amendmentno11a0097.jpg	Edgar Link	pending
gohealth-amendmentno11a0098.jpg	Edgar Link	pending
gohealth-amendmentno11a0099.jpg	Edgar Link	pending
gohealth-amendmentno11a0100.jpg	Edgar Link	pending
gohealth-amendmentno11a0101.jpg	Edgar Link	pending
gohealth-amendmentno11a0102.jpg	Edgar Link	pending
gohealth-amendmentno11a0103.jpg	Edgar Link	pending
gohealth-amendmentno11a0104.jpg	Edgar Link	pending
gohealth-amendmentno11a0105.jpg	Edgar Link	pending
gohealth-amendmentno11a0106.jpg	Edgar Link	pending
gohealth-amendmentno11a0107.jpg	Edgar Link	pending
gohealth-amendmentno11a0108.jpg	Edgar Link	pending
gohealth-amendmentno11a0109.jpg	Edgar Link	pending
gohealth-amendmentno11a0110.jpg	Edgar Link	pending
gohealth-amendmentno11a0111.jpg	Edgar Link	pending
gohealth-amendmentno11a0112.jpg	Edgar Link	pending
gohealth-amendmentno11a0113.jpg	Edgar Link	pending
gohealth-amendmentno11a0114.jpg	Edgar Link	pending
gohealth-amendmentno11a0115.jpg	Edgar Link	pending
gohealth-amendmentno11a0116.jpg	Edgar Link	pending
gohealth-amendmentno11a0117.jpg	Edgar Link	pending
gohealth-amendmentno11a0118.jpg	Edgar Link	pending
gohealth-amendmentno11a0119.jpg	Edgar Link	pending
gohealth-amendmentno11a0120.jpg	Edgar Link	pending
gohealth-amendmentno11a0121.jpg	Edgar Link	pending
gohealth-amendmentno11a0122.jpg	Edgar Link	pending
gohealth-amendmentno11a0123.jpg	Edgar Link	pending
gohealth-amendmentno11a0124.jpg	Edgar Link	pending
gohealth-amendmentno11a0125.jpg	Edgar Link	pending
gohealth-amendmentno11a0126.jpg	Edgar Link	pending
gohealth-amendmentno11a0127.jpg	Edgar Link	pending
gohealth-amendmentno11a0128.jpg	Edgar Link	pending
gohealth-amendmentno11a0129.jpg	Edgar Link	pending
gohealth-amendmentno11a0130.jpg	Edgar Link	pending
gohealth-amendmentno11a0131.jpg	Edgar Link	pending
gohealth-amendmentno11a0132.jpg	Edgar Link	pending
gohealth-amendmentno11a0133.jpg	Edgar Link	pending
gohealth-amendmentno11a0134.jpg	Edgar Link	pending
gohealth-amendmentno11a0135.jpg	Edgar Link	pending
gohealth-amendmentno11a0136.jpg	Edgar Link	pending
gohealth-amendmentno11a0137.jpg	Edgar Link	pending
gohealth-amendmentno11a0138.jpg	Edgar Link	pending
gohealth-amendmentno11a0139.jpg	Edgar Link	pending
gohealth-amendmentno11a0140.jpg	Edgar Link	pending
gohealth-amendmentno11a0141.jpg	Edgar Link	pending
gohealth-amendmentno11a0142.jpg	Edgar Link	pending
gohealth-amendmentno11a0143.jpg	Edgar Link	pending
gohealth-amendmentno11a0144.jpg	Edgar Link	pending
gohealth-amendmentno11a0145.jpg	Edgar Link	pending
gohealth-amendmentno11a0146.jpg	Edgar Link	pending
gohealth-amendmentno11a0147.jpg	Edgar Link	pending
gohealth-amendmentno11a0148.jpg	Edgar Link	pending
gohealth-amendmentno11a0149.jpg	Edgar Link	pending
gohealth-amendmentno11a0150.jpg	Edgar Link	pending
gohealth-amendmentno11a0151.jpg	Edgar Link	pending
gohealth-amendmentno11a0152.jpg	Edgar Link	pending
gohealth-amendmentno11a0153.jpg	Edgar Link	pending
gohealth-amendmentno11a0154.jpg	Edgar Link	pending
gohealth-amendmentno11a0155.jpg	Edgar Link	pending
gohealth-amendmentno11a0156.jpg	Edgar Link	pending
gohealth-amendmentno11a0157.jpg	Edgar Link	pending
gohealth-amendmentno11a0158.jpg	Edgar Link	pending
gohealth-amendmentno11a0159.jpg	Edgar Link	pending
gohealth-amendmentno11a0160.jpg	Edgar Link	pending
gohealth-amendmentno11a0161.jpg	Edgar Link	pending
gohealth-amendmentno11a0162.jpg	Edgar Link	pending
gohealth-amendmentno11a0163.jpg	Edgar Link	pending
gohealth-amendmentno11a0164.jpg	Edgar Link	pending
gohealth-amendmentno11a0165.jpg	Edgar Link	pending
gohealth-amendmentno11a0166.jpg	Edgar Link	pending
gohealth-amendmentno11a0167.jpg	Edgar Link	pending
gohealth-amendmentno11a0168.jpg	Edgar Link	pending
gohealth-amendmentno11a0169.jpg	Edgar Link	pending
gohealth-amendmentno11a0170.jpg	Edgar Link	pending
gohealth-amendmentno11a0171.jpg	Edgar Link	pending
gohealth-amendmentno11a0172.jpg	Edgar Link	pending
gohealth-amendmentno11a0173.jpg	Edgar Link	pending
gohealth-amendmentno11a0174.jpg	Edgar Link	pending
gohealth-amendmentno11a0175.jpg	Edgar Link	pending
gohealth-amendmentno11a0176.jpg	Edgar Link	pending
gohealth-amendmentno11a0177.jpg	Edgar Link	pending
gohealth-amendmentno11a0178.jpg	Edgar Link	pending
gohealth-amendmentno11a0179.jpg	Edgar Link	pending
gohealth-amendmentno11a0180.jpg	Edgar Link	pending
gohealth-amendmentno11a0181.jpg	Edgar Link	pending
gohealth-amendmentno11a0182.jpg	Edgar Link	pending
gohealth-amendmentno11a0183.jpg	Edgar Link	pending
gohealth-amendmentno11a0184.jpg	Edgar Link	pending
gohealth-amendmentno11a0185.jpg	Edgar Link	pending
gohealth-amendmentno11a0186.jpg	Edgar Link	pending
gohealth-amendmentno11a0187.jpg	Edgar Link	pending
gohealth-amendmentno11a0188.jpg	Edgar Link	pending
gohealth-amendmentno11a0189.jpg	Edgar Link	pending
gohealth-amendmentno11a0190.jpg	Edgar Link	pending
gohealth-amendmentno11a0191.jpg	Edgar Link	pending
gohealth-amendmentno11a0192.jpg	Edgar Link	pending
gohealth-amendmentno11a0193.jpg	Edgar Link	pending
gohealth-amendmentno11a0194.jpg	Edgar Link	pending
gohealth-amendmentno11a0195.jpg	Edgar Link	pending
gohealth-amendmentno11a0196.jpg	Edgar Link	pending
gohealth-amendmentno11a0197.jpg	Edgar Link	pending
gohealth-amendmentno11a0198.jpg	Edgar Link	pending
gohealth-amendmentno11a0199.jpg	Edgar Link	pending
gohealth-amendmentno11a0200.jpg	Edgar Link	pending
gohealth-amendmentno11a0201.jpg	Edgar Link	pending
gohealth-amendmentno11a0202.jpg	Edgar Link	pending
gohealth-amendmentno11a0203.jpg	Edgar Link	pending
gohealth-amendmentno11a0204.jpg	Edgar Link	pending
gohealth-amendmentno11a0205.jpg	Edgar Link	pending
gohealth-amendmentno11a0206.jpg	Edgar Link	pending
gohealth-amendmentno11a0207.jpg	Edgar Link	pending
gohealth-amendmentno11a0208.jpg	Edgar Link	pending
gohealth-amendmentno11a0209.jpg	Edgar Link	pending
gohealth-amendmentno11a0210.jpg	Edgar Link	pending
gohealth-amendmentno11a0211.jpg	Edgar Link	pending
gohealth-amendmentno11a0212.jpg	Edgar Link	pending
gohealth-amendmentno11a0213.jpg	Edgar Link	pending
gohealth-amendmentno11a0214.jpg	Edgar Link	pending
gohealth-amendmentno11a0215.jpg	Edgar Link	pending
gohealth-amendmentno11a0216.jpg	Edgar Link	pending
gohealth-amendmentno11a0217.jpg	Edgar Link	pending
gohealth-amendmentno11a0218.jpg	Edgar Link	pending
gohealth-amendmentno11a0219.jpg	Edgar Link	pending
gohealth-amendmentno11a0220.jpg	Edgar Link	pending
gohealth-amendmentno11a0221.jpg	Edgar Link	pending
gohealth-amendmentno11a0222.jpg	Edgar Link	pending
gohealth-amendmentno11a0223.jpg	Edgar Link	pending
gohealth-amendmentno11a0224.jpg	Edgar Link	pending
gohealth-amendmentno11a0225.jpg	Edgar Link	pending
gohealth-amendmentno11a0226.jpg	Edgar Link	pending
gohealth-amendmentno11a0227.jpg	Edgar Link	pending
gohealth-amendmentno11a0228.jpg	Edgar Link	pending
gohealth-amendmentno11a0229.jpg	Edgar Link	pending
gohealth-amendmentno11a0230.jpg	Edgar Link	pending
gohealth-amendmentno11a0231.jpg	Edgar Link	pending
gohealth-amendmentno11a0232.jpg	Edgar Link	pending
gohealth-amendmentno11a0233.jpg	Edgar Link	pending
gohealth-amendmentno11a0234.jpg	Edgar Link	pending
gohealth-amendmentno11a0235.jpg	Edgar Link	pending
gohealth-amendmentno11a0236.jpg	Edgar Link	pending
gohealth-amendmentno11a0237.jpg	Edgar Link	pending
gohealth-amendmentno11a0238.jpg	Edgar Link	pending
gohealth-amendmentno11a0239.jpg	Edgar Link	pending
gohealth-amendmentno11a0240.jpg	Edgar Link	pending
gohealth-amendmentno11a0241.jpg	Edgar Link	pending
gohealth-amendmentno11a0242.jpg	Edgar Link	pending
gohealth-amendmentno11a0243.jpg	Edgar Link	pending
gohealth-amendmentno11a0244.jpg	Edgar Link	pending
gohealth-amendmentno11a0245.jpg	Edgar Link	pending
gohealth-amendmentno11a0246.jpg	Edgar Link	pending
gohealth-amendmentno11a0247.jpg	Edgar Link	pending
gohealth-amendmentno11a0248.jpg	Edgar Link	pending
gohealth-amendmentno11a0249.jpg	Edgar Link	pending
gohealth-amendmentno11a0250.jpg	Edgar Link	pending
gohealth-amendmentno11a0251.jpg	Edgar Link	pending
gohealth-amendmentno11a0252.jpg	Edgar Link	pending
gohealth-amendmentno11a0253.jpg	Edgar Link	pending
gohealth-amendmentno11a0254.jpg	Edgar Link	pending
gohealth-amendmentno11a0255.jpg	Edgar Link	pending
gohealth-amendmentno11a0256.jpg	Edgar Link	pending
gohealth-amendmentno11a0257.jpg	Edgar Link	pending
gohealth-amendmentno11a0258.jpg	Edgar Link	pending
gohealth-amendmentno11a0259.jpg	Edgar Link	pending
gohealth-amendmentno11a0260.jpg	Edgar Link	pending
gohealth-amendmentno11a0261.jpg	Edgar Link	pending
gohealth-amendmentno11a0262.jpg	Edgar Link	pending
gohealth-amendmentno11a0263.jpg	Edgar Link	pending
gohealth-amendmentno11a0264.jpg	Edgar Link	pending
gohealth-amendmentno11a0265.jpg	Edgar Link	pending
gohealth-amendmentno11a0266.jpg	Edgar Link	pending
gohealth-amendmentno11a0267.jpg	Edgar Link	pending
gohealth-amendmentno11a0268.jpg	Edgar Link	pending
gohealth-amendmentno11a0269.jpg	Edgar Link	pending
gohealth-amendmentno11a0270.jpg	Edgar Link	pending
gohealth-amendmentno11a0271.jpg	Edgar Link	pending
gohealth-amendmentno11a0272.jpg	Edgar Link	pending
gohealth-amendmentno11a0273.jpg	Edgar Link	pending
gohealth-amendmentno11a0274.jpg	Edgar Link	pending
gohealth-amendmentno11a0275.jpg	Edgar Link	pending
gohealth-amendmentno11a0276.jpg	Edgar Link	pending
gohealth-amendmentno11a0277.jpg	Edgar Link	pending
gohealth-amendmentno11a0278.jpg	Edgar Link	pending
gohealth-amendmentno11a0279.jpg	Edgar Link	pending
gohealth-amendmentno11a0280.jpg	Edgar Link	pending
gohealth-amendmentno11a0281.jpg	Edgar Link	pending
gohealth-amendmentno11a0282.jpg	Edgar Link	pending
gohealth-amendmentno11a0283.jpg	Edgar Link	pending
gohealth-amendmentno11a0284.jpg	Edgar Link	pending
gohealth-amendmentno11a0285.jpg	Edgar Link	pending
gohealth-amendmentno11a0286.jpg	Edgar Link	pending
gohealth-amendmentno11a0287.jpg	Edgar Link	pending
gohealth-amendmentno11a0288.jpg	Edgar Link	pending
gohealth-amendmentno11a0289.jpg	Edgar Link	pending
gohealth-amendmentno11a0290.jpg	Edgar Link	pending
gohealth-amendmentno11a0291.jpg	Edgar Link	pending
gohealth-amendmentno11a0292.jpg	Edgar Link	pending
gohealth-amendmentno11a0293.jpg	Edgar Link	pending
gohealth-amendmentno11a0294.jpg	Edgar Link	pending
gohealth-amendmentno11a0295.jpg	Edgar Link	pending
gohealth-amendmentno11a0296.jpg	Edgar Link	pending
gohealth-amendmentno11a0297.jpg	Edgar Link	pending
gohealth-amendmentno11a0298.jpg	Edgar Link	pending
gohealth-amendmentno11a0299.jpg	Edgar Link	pending
gohealth-amendmentno11a0300.jpg	Edgar Link	pending
gohealth-amendmentno11a0301.jpg	Edgar Link	pending
gohealth-amendmentno11a0302.jpg	Edgar Link	pending
gohealth-amendmentno11a0303.jpg	Edgar Link	pending
gohealth-amendmentno11a0304.jpg	Edgar Link	pending
gohealth-amendmentno11a0305.jpg	Edgar Link	pending
gohealth-amendmentno11a0306.jpg	Edgar Link	pending
gohealth-amendmentno11a0307.jpg	Edgar Link	pending
gohealth-amendmentno11a0308.jpg	Edgar Link	pending
gohealth-amendmentno11a0309.jpg	Edgar Link	pending
gohealth-amendmentno11a0310.jpg	Edgar Link	pending
gohealth-amendmentno11a0311.jpg	Edgar Link	pending
gohealth-amendmentno11a0312.jpg	Edgar Link	pending
gohealth-amendmentno11a0313.jpg	Edgar Link	pending
gohealth-amendmentno11a0314.jpg	Edgar Link	pending
gohealth-amendmentno11a0315.jpg	Edgar Link	pending
gohealth-amendmentno11a0316.jpg	Edgar Link	pending
gohealth-amendmentno11a0317.jpg	Edgar Link	pending
gohealth-amendmentno11a0318.jpg	Edgar Link	pending
gohealth-amendmentno11a0319.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
goco-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GOCO
GoHealth, Inc. Stock $goco

2023 Q4 Form 10-K Financial Statement

#000180822024000017 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOCO GoHealth, Inc. Stock $goco

2023 Q4 Form 10-K Financial Statement

#000180822024000017 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOCO
GoHealth, Inc. Stock $goco